| EGFR Mutations in Non–Small-Cell Lung Cancer: Analysis of a Large Series of Cases and Development of a Rapid and Sensitive Method for Diagnostic Screening … A Marchetti, C Martella, L Felicioni, F Barassi, S Salvatore, A Chella, ... Journal of clinical oncology 23 (4), 857-865, 2005 | 1091 | 2005 |
| Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Harboring BRAF Mutations A Marchetti, L Felicioni, S Malatesta, M Grazia Sciarrotta, L Guetti, ... Journal of clinical oncology 29 (26), 3574-3579, 2011 | 702 | 2011 |
| Increased MET Gene Copy Number Negatively Affects Survival of Surgically Resected Non–Small-Cell Lung Cancer Patients F Cappuzzo, A Marchetti, M Skokan, E Rossi, S Gajapathy, L Felicioni, ... Journal of clinical oncology 27 (10), 1667-1674, 2009 | 635 | 2009 |
| 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up J Vansteenkiste, L Crino, C Dooms, JY Douillard, C Faivre-Finn, E Lim, ... Annals of Oncology 25 (8), 1462-1474, 2014 | 588 | 2014 |
| The Hippo effector YAP promotes resistance to RAF-and MEK-targeted cancer therapies L Lin, AJ Sabnis, E Chan, V Olivas, L Cade, E Pazarentzos, S Asthana, ... Nature genetics 47 (3), 250-256, 2015 | 582 | 2015 |
| microRNAs derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing lung cancer R Cazzoli, F Buttitta, M Di Nicola, S Malatesta, A Marchetti, WN Rom, ... Journal of thoracic oncology 8 (9), 1156-1162, 2013 | 512 | 2013 |
| IDH1 mutations at residue p.R132 (IDH1R132) occur frequently in high‐grade gliomas but not in other solid tumors FE Bleeker, S Lamba, S Leenstra, D Troost, T Hulsebos, WP Vandertop, ... Human mutation 30 (1), 7-11, 2009 | 496 | 2009 |
| 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer WEE Eberhardt, D De Ruysscher, W Weder, C Le Pechoux, P De Leyn, ... Annals of Oncology 26 (8), 1573-1588, 2015 | 428 | 2015 |
| Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer KM Kerr, L Bubendorf, MJ Edelman, A Marchetti, T Mok, S Novello, ... Annals of Oncology 25 (9), 1681-1690, 2014 | 379 | 2014 |
| Survivin gene expression in early‐stage non‐small cell lung cancer M Falleni, C Pellegrini, A Marchetti, B Oprandi, F Buttitta, F Barassi, ... The Journal of Pathology: A Journal of the Pathological Society of Great …, 2003 | 367 | 2003 |
| Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop R Pirker, FJF Herth, KM Kerr, M Filipits, M Taron, D Gandara, FR Hirsch, ... Journal of Thoracic Oncology 5 (10), 1706-1713, 2010 | 362 | 2010 |
| 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease B Besse, A Adjei, P Baas, P Meldgaard, M Nicolson, L Paz-Ares, M Reck, ... Annals of Oncology 25 (8), 1475-1484, 2014 | 292 | 2014 |
| Association between Cigarette Smoking and FHIT Gene Alterations in Lung Cancer G Sozzi, L Sard, L De Gregorio, A Marchetti, K Musso, F Buttitta, ... Cancer research 57 (11), 2121-2123, 1997 | 279 | 1997 |
| Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas M Barbareschi, F Buttitta, L Felicioni, S Cotrupi, F Barassi, ... Clinical Cancer Research 13 (20), 6064-6069, 2007 | 257 | 2007 |
| Testing for ROS1 in non-small cell lung cancer: a review with recommendations L Bubendorf, R Büttner, F Al-Dayel, M Dietel, G Elmberger, K Kerr, ... Virchows Archiv 469, 489-503, 2016 | 255 | 2016 |
| AKT1E17K in human solid tumours FE Bleeker, L Felicioni, F Buttitta, S Lamba, L Cardone, M Rodolfo, ... Oncogene 27 (42), 5648-5650, 2008 | 251 | 2008 |
| A unique microRNA signature associated with plaque instability in humans F Cipollone, L Felicioni, R Sarzani, S Ucchino, F Spigonardo, C Mandolini, ... Stroke 42 (9), 2556-2563, 2011 | 224 | 2011 |
| Assessing EGFR mutations. A Marchetti, L Felicioni, F Buttitta New England Journal of Medicine 354, 526-528, 2006 | 213 | 2006 |
| Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project FH Blackhall, S Peters, L Bubendorf, U Dafni, KM Kerr, H Hager, ... Journal of clinical oncology 32 (25), 2780-2787, 2014 | 211 | 2014 |
| Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features F Buttitta, F Barassi, G Fresu, L Felicioni, A Chella, D Paolizzi, G Lattanzio, ... International journal of cancer 119 (11), 2586-2591, 2006 | 211 | 2006 |
